These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 19417110)

  • 1. Effects of angiotensin-converting enzyme inhibitor versus valsartan on cellular signaling events in heart transplant.
    White M; Ross H; Levesque S; Whittom L; Pelletier GB; Racine N; Meloche S; Voisin L
    Ann Pharmacother; 2009 May; 43(5):831-9. PubMed ID: 19417110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
    J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
    Solomon SD; Skali H; Anavekar NS; Bourgoun M; Barvik S; Ghali JK; Warnica JW; Khrakovskaya M; Arnold JM; Schwartz Y; Velazquez EJ; Califf RM; McMurray JV; Pfeffer MA
    Circulation; 2005 Jun; 111(25):3411-9. PubMed ID: 15967846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valsartan in chronic heart failure.
    Ripley TL
    Ann Pharmacother; 2005 Mar; 39(3):460-9. PubMed ID: 15687480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transforming growth factor-beta1 is associated with kidney damage in patients with essential hypertension: renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker.
    Zhu S; Liu Y; Wang L; Meng QH
    Nephrol Dial Transplant; 2008 Sep; 23(9):2841-6. PubMed ID: 18390891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system.
    Lassila M; Davis BJ; Allen TJ; Burrell LM; Cooper ME; Cao Z
    Clin Sci (Lond); 2003 Apr; 104(4):341-7. PubMed ID: 12653675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on beta-adrenoceptor signaling in heart failure produced by myocardial Infarction in rabbits: reversal of altered expression of beta-adrenoceptor kinase and G i alpha.
    Makino T; Hattori Y; Matsuda N; Onozuka H; Sakuma I; Kitabatake A
    J Pharmacol Exp Ther; 2003 Jan; 304(1):370-9. PubMed ID: 12490614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: a randomized multicenter study.
    Andrés A; Morales E; Morales JM; Bosch I; Campo C; Ruilope LM;
    Transplant Proc; 2006 Oct; 38(8):2419-23. PubMed ID: 17097955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valsartan-induced hematocrit changes in renal transplant patients.
    Flores CA; Ardiles LG; Aros CA; Muñoz CC; Schneider HO; Ramírez JA; Jerez V; Valderrama MG; Mezzano SA
    Transplant Proc; 2005 Apr; 37(3):1586-8. PubMed ID: 15866681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial.
    Cohn JN; Anand IS; Latini R; Masson S; Chiang YT; Glazer R;
    Circulation; 2003 Sep; 108(11):1306-9. PubMed ID: 12939207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis.
    Smith DG; Cerulli A; Frech FH
    Clin Ther; 2005 Jun; 27(6):951-9. PubMed ID: 16117995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effect of valsartan and lisinopril on autonomic nervous system activity in chronic heart failure.
    De Tommasi E; Iacoviello M; Romito R; Ceconi C; Guida P; Massari F; Francolini G; Bertocchi F; Ferrari R; Rizzon P; Pitzalis MV
    Am Heart J; 2003 Nov; 146(5):E17. PubMed ID: 14597946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of valsartan on the expression of angiotensin II receptors in the lung of chronic antigen exposure rats.
    Wang T; Yin KS; Liu KY; Lu GJ; Li YH; Chen JD
    Chin Med J (Engl); 2008 Nov; 121(22):2312-9. PubMed ID: 19080339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
    Miyajima K; Minatoguchi S; Ito Y; Hukunishi M; Matsuno Y; Kakami M; Kawasaki M; Nishigaki K; Takemura G; Fujiwara H
    Hypertens Res; 2007 Apr; 30(4):307-13. PubMed ID: 17541209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mechanism of reversion of myocardial interstitial fibrosis in diabetic cardiomyopathy by valsartan].
    Zhong M; Zhang Y; Miao Y; Li L; Gong HP; Ma X; Sun H; Zhang W
    Zhonghua Yi Xue Za Zhi; 2006 Jan; 86(4):232-6. PubMed ID: 16677501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular signaling mediated by angiotensin II type 1A receptor blockade leading to attenuation of renal dysfunction-associated heart failure.
    Li Y; Takemura G; Okada H; Miyata S; Maruyama R; Esaki M; Kanamori H; Li L; Ogino A; Ohno T; Kondo T; Nakagawa M; Minatoguchi S; Fujiwara T; Fujiwara H
    J Card Fail; 2007 Mar; 13(2):155-62. PubMed ID: 17395057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valsartan versus ACE inhibition after bare metal stent implantation--results of the VALVACE trial.
    Peters S; Trümmel M; Meyners W; Koehler B; Westermann K
    Int J Cardiol; 2005 Feb; 98(2):331-5. PubMed ID: 15686787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.
    Ferri C; Croce G; Desideri G
    Adv Ther; 2008 Apr; 25(4):300-20. PubMed ID: 18449492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcriptional and translational regulation of calpain in the rat heart after myocardial infarction--effects of AT(1) and AT(2) receptor antagonists and ACE inhibitor.
    Sandmann S; Yu M; Unger T
    Br J Pharmacol; 2001 Feb; 132(3):767-77. PubMed ID: 11159730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.